Sugi Predict

Sugi Predict / Compounds / SCHEMBL1104891

SCHEMBL1104891

SCHEMBL1104891

COc1cc(OC)c(C(=O)O)cc1Cc1cccc(Cl)c1F

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 1/20 0.56
▸ MRGPRX4 Q96LA9 7/20 0.44
▸ KDM4E B2RXH2 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ CYP2C9 P11712 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ NOTUM Q6P988 1/20 0.41
▸ PLA2G4A P47712 2/20 0.40
▸ TP53 P04637 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ CSF1R P07333 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ CMA1 P23946 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4211289 0.99 METTL3 (0.55) METTL3MRGPRX4KDM4EALDH1A1HPGD
SCHEMBL4210123 0.91 METTL3 (0.55) METTL3MRGPRX4KDM4ECYP2C9HIF1A
SCHEMBL4207612 0.91 METTL3 (0.50) METTL3MRGPRX4KDM4EALDH1A1CSF1R
SCHEMBL14037269 0.90 METTL3 (0.55) METTL3MRGPRX4KDM4EHPGDHSD17B10
SCHEMBL16482308 0.90 METTL3 (0.50) METTL3MRGPRX4KDM4EALDH1A1HPGD
SCHEMBL1104898 0.90 METTL3 (0.49) METTL3KDM4EALDH1A1CSF1R
SCHEMBL4209881 0.89 METTL3 (0.48) METTL3MRGPRX4KDM4EALDH1A1HPGD
SCHEMBL14037419 0.86 ALDH1A1 (0.44) METTL3MRGPRX4KDM4EALDH1A1HPGD
SCHEMBL1104896 0.86 METTL3 (0.47) METTL3MRGPRX4KDM4EALDH1A1CSF1R
SCHEMBL1104880 0.85 METTL3 (0.48) METTL3MRGPRX4PLA2G4ACSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180265454-A1 Method for Producing 4-Oxoquinoline Compound JAPAN TOBACCO INC. (JP) 2018-09-20 — — US disclosed
EP-2906540-B1 AN IMPROVED PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR ZENTIVA KS (CZ) 2018-07-04 — — EP disclosed
EP-2906529-B9 A NEW PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR ZENTIVA KS (CZ) 2017-03-15 — — EP disclosed
EP-2906529-B1 A NEW PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR ZENTIVA KS (CZ) 2016-11-23 — — EP disclosed
EP-2190804-B1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES INC (US) 2015-11-18 — — EP disclosed
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-10-22 — — US disclosed
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-10-22 — — US disclosed
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-10-22 — — US disclosed
EP-1992607-B9 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-07-01 — — EP disclosed
EP-1992607-B9 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2015-07-01 — — EP disclosed
US-20090099366-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-04-16 — — US disclosed
WO-2009036161-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-03-19 — — WO disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 — — US disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 — — US disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 — — US disclosed
EP-1992607-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND Japan Tobacco, Inc. (JP) 2008-11-19 — — EP disclosed
EP-1992607-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND Japan Tobacco, Inc. (JP) 2008-11-19 — — EP disclosed
US-20080125594-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-05-29 — — US disclosed
US-20080125594-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-05-29 — — US disclosed
WO-2008033836-A2 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099366-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS TYMS, TYMP, POLB METTL3 2511/4885MRGPRX4 3845/4885KDM4E 764/4885
US-20150299104-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND IMPDH1, IMPDH2, CDK20 METTL3 938/4885MRGPRX4 2814/4885KDM4E 780/4885
US-20080125594-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS TYMS, TYMP, POLB METTL3 2511/4885MRGPRX4 3845/4885KDM4E 764/4885
US-20180265454-A1 Method for Producing 4-Oxoquinoline Compound IMPDH1, IMPDH2, CDK20 METTL3 938/4885MRGPRX4 2814/4885KDM4E 780/4885
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND IMPDH1, IMPDH2, CDK20 METTL3 938/4885MRGPRX4 2814/4885KDM4E 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.